Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | FPR1 | P21462 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275352 | 0.90 | MAPT (0.37) | MAPTPOLBNPSR1 | |
| SCHEMBL13571631 | 0.89 | MAPT (0.35) | MAPT | |
| SCHEMBL9010028 | 0.86 | GAA (0.38) | MAPTPOLBNPSR1 | |
| SCHEMBL7933762 | 0.85 | MAPT (0.33) | MAPTTDP1ALDH1A1 | |
| SCHEMBL13571378 | 0.82 | MAPT (0.33) | MAPTTDP1ALDH1A1 | |
| SCHEMBL2047496 | 0.81 | MAPT (0.45) | MAPTPOLBLMNAALDH1A1HSD17B10 | |
| SCHEMBL6317561 | 0.81 | RAB9A (0.38) | MAPTTDP1ALDH1A1HTT | |
| SCHEMBL3554608 | 0.81 | — | — | |
| SCHEMBL28589138 | 0.81 | MAPT (0.33) | MAPT | |
| SCHEMBL11340916 | 0.81 | MAPT (0.30) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974868-B2 | Compounds | ASTRAZENECA AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-6921830-B2 | Method for purifying an organic solvent for the purposes of absorption of maleic acid anhydride | BASF AKTIENGESELLSCHAFT (DE) | 2005-07-26 | — | — | US | disclosed |
| US-20040127726-A1 | Method for purifying an organic solvent for the purposes of absorption of maleic acid anhydride | BASF AKTIENGESELLSCHAFT (DE) | 2004-07-01 | — | — | US | disclosed |
| US-20030144305-A1 | Novel compounds | ASTRAZENECA AB | 2003-07-31 | — | — | US | disclosed |
| CN-1116315-C | Polypropylene resin composition and injection-molded article | GRAND POLYMER CO LTD (JP) | 2003-07-30 | — | — | CN | disclosed |
| CN-1236375-A | Polypropylene resin composition and injection-molded article | GRAND POLYMER CO LTD (JP) | 1999-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144305-A1 | Novel compounds | DPYD, TYMP, NUDT15 | MAPT 2926/4885POLB 197/4885NPSR1 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.